Agency Partners with Valeritas to Drive Awareness and Adoption of V-Go, an Innovative Insulin Delivery Device for Patients with Diabetes
NEW YORK, Dec. 10, 2018—Deutsch announced in partnership with Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company, that it has been named their patient partner agency for their V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option that is worn like a patch, for patients with diabetes.
Deutsch will handle all creative, media, and data analytics for V-Go’s direct-to-consumer efforts. A fully integrated pilot patient campaign is being planned for roll out in multiple U.S. metropolitan markets in the first half of 2019.
“Deutsch has a proven track record of telling brand stories that emotionally connect with consumers and elevate brands, so they’ll play a critical role in helping us develop a 360-marketing effort that will help empower millions of patients that currently struggle with insulin injections,” noted Valeritas’ President and CEO John Timberlake.
“We’re excited to work with V-Go and the Valeritas team, an ambitious group that is patient centric and committed to making an impact,” said Tyler Swerdloff-Helms, EVP, and Group Account Director. “They have a modern, unique and eloquent solution designed for patients with type 2 diabetes and a bold vision for the brand, and we can’t wait to help simplify lives for people with diabetes.”
The CEO of Deutsch New York, Val DiFebo, noted, “We can’t wait to get 2019 started. For new clients including Newman’s Own, Lactaid, Constant Contact and now V-Go, we’ll be showcasing a lineup of ambitious creative work designed to drive sales and deepen the brands’ engagement with consumers.”
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
More information is available at www.valeritas.com
Deutsch is an advertising, design, and digital agency known for its award-winning creative campaigns. Clients include Johnson & Johnson, AB InBev, PNC Bank, Newman’s Own, Taco Bell, Target, Dr Pepper, and Georgia-Pacific, among others. Deutsch has been named one of the most innovative companies in advertising by Fast Company and has regularly appeared on Advertising Age’s Agency A-List. For more information, visit www.Deutsch.com.